Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench ...

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...

US pharma giant Pfizer yesterday announced that it has entered into settlement agreements with generic drug manufacturers - ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...